An Open-labeled Trial With a Dose-escalation Part and a Parallel Group Design(1) Investigating Zalutumumab, an Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation as First Line Treatment of Patients With Cancer of the Head and Neck (1) The Parallel Group Part Was Cancelled

Trial Profile

An Open-labeled Trial With a Dose-escalation Part and a Parallel Group Design(1) Investigating Zalutumumab, an Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation as First Line Treatment of Patients With Cancer of the Head and Neck (1) The Parallel Group Part Was Cancelled

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2013

At a glance

  • Drugs Zalutumumab (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Sep 2011 Planned end date changed from 1 Feb 2012 to 1 Oct 2010 as reported by ClinicalTrials.gov.
    • 18 Nov 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Planned end date changed from 1 Sep 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top